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We assessed clearance rates of 14 high-risk human papillomavirus (hrHPV) types in hrHPV-positive women with normal cytology
and borderline/mild dyskaryosis (BMD) in a population-based cervical screening cohort of 44102 women. The 6-month hrHPV
type-specific clearance rates, that is, clearance of the same type as detected at baseline, in women with normal and BMD smears
were 43% (95% confidence interval (CI) 39–47) and 29% (95% CI 24–34), respectively. Corresponding 18-month clearance rates
were markedly higher, namely 65% (95% CI 60–69) and 41% (95% CI 36–47), respectively. The lowest clearance rates in women
with normal cytology were observed for HPV16, HPV18, HPV31, and HPV33. Significantly reduced 18-month clearance rates at a
significance level of 1% were observed for HPV16 (49%, 95% CI 41–59) and HPV31 (50%, 95% CI 39–63) in women with normal
cytology, and for HPV16 (19%, 95% CI 12–29) in women with BMD. Among women who did not clear hrHPV, women with HPV16
persistence displayed an increased detection rate of XCIN3 (normal Po0.0001; BMD, P¼0.005). The type-specific differences
in clearance rates indicate the potential value of hrHPV genotyping in screening programs. Our data support close surveillance
(i.e. referral directly, or within 6 months) of women with HPV16 and are inconclusive for surveillance of women with HPV18, HPV31,
and HPV33. For the other hrHPV-positive women, it seems advisable to adopt a conservative management with a long waiting
period, as hrHPV clearance is markedly higher after 18 months than after 6 months and the risk for XCIN3 is low.
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Persistent infection with high-risk human papillomavirus (hrHPV)
is the primary cause for the development of cervical carcinoma
(Walboomers et al, 1999; Bosch et al, 2002). Several studies
have shown that hrHPV testing can improve identification of
women who have or will develop high-grade cervical intraepithelial
neoplasia or cervical cancer (XCIN2) (Clavel et al, 2001;
Kulasingam et al, 2002; Cuzick et al, 2003; Peto et al, 2004;
Kotaniemi-Talonen et al, 2005; Cuzick et al, 2006).
In the search of an optimal screening algorithm using hrHPV
testing, it is essential to determine the time point at which the
majority of the screening participants has cleared the virus and can
be referred back to regular screening. Also, future screening may
involve genotyping as different hrHPV types show markedly
different risks of high-grade CIN. Particularly HPV16-positive
women are more likely to develop XCIN2 than hrHPV-positive
women infected with a non-HPV16 type (Bulkmans et al, 2005;
Castle et al, 2005; Khan et al, 2005; Berkhof et al,2 0 0 6 ) .S of a r ,l i t t l e
is known about type-specific clearance rates of hrHPV infections.
Some studies reported relatively low clearance of HPV16 infections
compared with other high-risk HPV infections, but samples sizes
were small and results were not statistically significant (Ho et al,
1998; Molano et al, 2003; Richardson et al,2 0 0 3 ) .
To obtain information about the course of 14 different hrHPV
types, we investigated repeated hrHPV typing results collected
from a large population-based screening cohort. We assessed




From January 1999 to September 2002, 44102 women between 30
and 60 years of age invited for the regular Dutch cervical screening
programme participated in the Population-Based Screening
Amsterdam (POBASCAM) trial (Bulkmans et al, 2004). In this
prospective randomised controlled trial, the efficacy of hrHPV
testing in conjunction with cytology (intervention group) is
compared with that of classical cytology alone (control group,
hrHPV results blinded) in the setting of population-based cervical
screening. The design of the POBASCAM trial and the baseline
results have been described previously (Bulkmans et al, 2004). All
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sWe included all hrHPV-positive participants who were advised
to return for repeat testing at 6 and 18 months according to the
study design, that is, participants with normal cytology from
the intervention group (n¼763) and participants with borderline
or mild dyskaryosis (BMD) from the intervention (n¼185) and
control (n¼196) group. Borderline/mild dyskaryosis is equivalent
to ASC-US, ASC-H, LSIL, AGC and AGC favour neoplastic,
according to the Bethesda 2001 classification (Bulk et al, 2004).
Women who were positive for hrHPV by generic hrHPV test, but
negative after typing, were excluded from the analysis (n¼57),
leaving 713 hrHPV-positive participants with normal cytology
carrying 865 hrHPV infections, and 374 hrHPV-positive partici-
pants with BMD carrying 491 hrHPV infections.
For all included participants, hrHPV testing and typing
were performed both at baseline and at 6 and 18 months of
follow-up. Participants with a baseline normal smear were referred
for colposcopy at 6 months in case the repeat smear displayed
moderate dyskaryosis or worse (4BMD; equivalent to HSIL
according to Bethesda 2001; Bulk et al, 2004). Participants with
baseline BMD were referred for colposcopy at 6 months in case the
repeat smear result was XBMD in the control group and either
4BMD or hrHPV-positive BMD in the intervention group. A
flowchart of the screening management of women who were
advised to return for repeat testing is presented in Figure 1.
Cytology and hrHPV testing
Conventional cytological smears were prepared with a Cervex
brush
s and classified according to the Dutch CISOE-A classifica-
tion, which can be translated to the Bethesda 2001 classification
(Bulk et al, 2004). After taking the smear, the brush was placed
in a vial containing collection medium (i.e. 5ml PBS and 0.5%
thiomersal) for hrHPV-DNA testing. Detection of hrHPV-DNA
was performed by a generic hrHPV test, that is, GP5þ/6þ PCR-
enzyme immunoassay (GP5þ/6þ PCR EIA), using a cocktail
of 14 high-risk types, that is, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, and 68 (Jacobs et al, 1997). GP5þ/6þ PCR EIA-positive
cases were subsequently typed by reverse line blotting (RLB)
(van den Brule et al, 2002). Interpretation of cytology and
hrHPV testing by technicians was performed blinded to the other
test result.
Statistical analysis
We calculated the clearance rates of 14 hrHPV types with type-
specific clearance defined as a negative RLB test result for that
HPV type in the follow-up smear. Women treated for XCIN2 were
considered not to have cleared the virus during the study period of
18 months. Participants were censored if lost to follow-up, or if a
biopsy was taken with CIN0/1 as histological outcome. Time was
set equal to the target repeat date (i.e. 6 or 18 months). The 18-
month clearance rates were estimated by Kaplan–Meier method.
The clearance rates were accompanied by 95% confidence intervals
(95% CI) (Klein and Moeschberger, 1997). Data were stratified in
three age categories corresponding to the age at the first round,
second round, and at rounds 3–7 in nationwide screening (i.e. 29–
33, 34–38, and 39–60 years). Differences in 6-month clearance
rates were assessed by Cochran’s Mantel–Haenszel test and
differences in 18-month clearance rates were assessed by stratified
log-rank testing (Heimann and Neuhaus, 1998). The level of
statistical significance was set at 0.01. The main analyses did not
distinguish whether the hrHPV infection was observed in a women
with single or multiple hrHPV types. Analyses were repeated for
women with single hrHPV infections only. To examine an effect of
coexisting hrHPV infections on clearance, type-specific clearance
rates in single and multiple infections were compared by stratified
log-rank testing. For clinical practice it might be more feasible to
define clearance as a negative hrHPV follow-up test result for any
hrHPV type. Therefore, analyses were repeated with clearance
defined as a negative generic hrHPV test result.
To assess the hrHPV type-specific risk for XCIN3 in women
who did not clear the hrHPV infection (ie. viral persistence),
participants were selected that revealed RLB positivity during
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Figure 1 Management of women in the POBASCAM study who were advised to return for repeat testing at 6 and 18 months.
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sassociation between persistent hrHPV type and XCIN3 was
assessed by Cochran’s Mantel–Haenszel test stratified for age.
To examine the effect of coexisting hrHPV infections, XCIN3 rates
in women with single and multiple hrHPV infections were
compared by Cochran’s Mantel–Haenszel testing, stratified




The mean ages of hrHPV-positive women with normal cytology and
BMD at baseline were 38.3 years (range 29–60 years) and 36.2 years
(range 29–59 years), respectively. Of women with normal cytology,
23.1% (165/713) did not respond to the follow-up invitation at 6
months and 28.0% (146/522) did not respond to the second follow-
up invitation at 18 months. For women with BMD, the nonresponse
rates to follow-up invitations at 6 and 18 months were 9.9% (37/374)
and 28.8% (53/184), respectively. Loss to follow-up was not hrHPV
type specific (P40.05 for each type). Multiple hrHPV infections were
less prevalent in women with normal cytology than in women with
BMD (18.0 vs 24.6%, P¼0.011).
Type-specific clearance rates for hrHPV infections in
normal cytology
The 6- and 18-month clearance rates of the different hrHPV types
in women with normal cytology at baseline are presented in
Table 1. The overall type-specific hrHPV clearance rates at 6 and
18 months were 43% (95% CI 39–47) and 65% (95% CI 60–69).
HPV16 infections displayed a significantly lower 18-month
clearance rate (49%, 95% CI 41–59) than other hrHPV infections
(69%, 95% CI 65–74; P¼0.002). The second, third, and fourth
lowest 18-month clearance rates were observed for HPV31, HPV33,
and HPV18 infections, respectively, but the clearance rate was
significantly reduced only for HPV31 (P¼0.008). When compar-
ing single and multiple infections at baseline, none of the hrHPV
types showed marked differences in clearance rates (data not
shown). Notably, 18-month clearance for HPV16 was 48% (95% CI
38–58) in women with a single infection and 56% (95% CI 39–75)
in women with a multiple infection (P¼0.310).
When defining clearance as a negative generic hrHPV test result
instead of a negative RLB result for a specific hrHPV type, overall
hrHPV clearance rates at 6 and 18 months were slightly lower, that
is, 36% (95% CI 31–41) and 56% (95% CI 52–60), respectively.
The lowest clearance rates were again found for HPV16, HPV18,
HPV31, and HPV33 infections.
Type-specific clearance rates for hrHPV infections in BMD
For hrHPV infections in women with a BMD smear at baseline,
6 and 18-month type-specific clearance rates were 29% (95%
CI 24–34) and 41% (95% CI 36–47) (Table 2).
As was the case for women with normal cytology, HPV16
infections in women with BMD showed a significantly reduced 18-
month clearance rate (19%, 95% CI 12–29) compared with other
hrHPV infections (49%, 95% CI 43–56; Po0.0001). For HPV31
and HPV33 infections in BMD, clearance rates were also low, but
rates were not significantly lower than for other hrHPV infections.
Similar clearance rates were observed when the analysis was
repeated for women with single infections only. None of the
hrHPV types showed marked differences in clearance rates when
comparing single infections at baseline to multiple infections at
baseline (data not shown).
When clearance was defined as a negative generic hrHPV test
instead of a negative RLB test for a specific hrHPV type, hrHPV
clearance rates at 6 and 18 months were 25% (95% CI 19–31) and
32% (95% CI 26–38), respectively. The three types with the lowest
18-month clearance rates were again HPV16, HPV31, and HPV33.
High-grade lesions in women with persistent hrHPV
infections
The 18-month hrHPV type-specific detection rate of XCIN3 in
women who showed persistence for at least one hrHPV type was
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s12% (95% CI 9–17) when baseline cytology was read as normal
and 26% (95% CI 19–33) in case of BMD (Table 3). Women with a
persistent HPV16 infection had significantly increased 18-month
XCIN3 detection rates (25% for baseline normal cytology (95% CI
17–36; Po0.0001) and 38% for BMD (95% CI 27–51; P¼0.005),
respectively). Similar results were obtained when repeating
the analysis only for women with a single infection at baseline.
After exclusion of women with HPV16, marginal increases in
XCIN3 detection rates (Po0.1) were found in women with HPV18
and HPV31 persistence. It should be noted, however, that
subgroups were small.
Interestingly, for normal cytology and BMD combined, the
XCIN3 detection rate in women with persistence of at least one
hrHPV type was higher in women with a single hrHPV infection
(20%, 95% CI 15–25) than in women with multiple hrHPV
infections (12%, 95% CI 7–20; P¼0.015). This difference was most
pronounced in women with HPV16 at baseline, as the XCIN3 rate
was 35% (95% CI 26–44) when carrying a single infection at
baseline and 14% (95% CI 6–32) when carrying multiple infections
at baseline (P¼0.022).
DISCUSSION
In our population-based screening cohort, we studied the type-
specific clearance in women with an hrHPV infection. Overall 18-
month clearance rates in women with normal cytology at baseline
were about 1.5 times higher than those in women with BMD (65 vs
41%). Besides, about one-third of the women who cleared the virus
within 18 months showed clearance between 6 and 18 months. The
lowest clearance rates were observed for HPV16, HPV18, HPV31,
and HPV33. Only HPV16 and HPV31 were statistically distinct
from the other hrHPV types in women with normal cytology, and
only HPV16 and HPV33 were statistically distinct in women
with BMD. The relatively low clearance rate of HPV16 could also
have been deduced from earlier studies (Ho et al, 1998; Molano
et al, 2003; Richardson et al, 2003). However, in these studies,
sample sizes were generally smaller, and either results did not
reach statistical significance or many HPV types were grouped
together. Furthermore, we found that among women who did not
clear the HPV infection, HPV16-positive women displayed XCIN3
lesions more often than women who had a persistent infection with
another hrHPV type. Finally, we found that the XCIN3 detection
rate in women with viral persistence was higher in women with a
single hrHPV infection than in women with multiple hrHPV
infections at baseline. This finding is in accordance with data of
other studies, which showed that multiple hrHPV infections
decrease in prevalence when comparing hrHPV-positive normal
cervices to increasing grades of cervical premalignant disease
(Lungu et al, 1992; Sasagawa et al, 2001; An et al, 2003).
Previously described data showed that besides HPV16, HPV18,
HPV31, and HPV33 also conferred an increased risk of XCIN3
(Castle et al, 2005; Khan et al, 2005; Berkhof et al, 2006). This
likely reflects the combined effects of differences in persistence
and oncogenic potential of these types compared with other
types and finds support by our data. Whereas HPV16 displayed
markedly decreased clearance rates and increased XCIN3
rates in case of persistence in both women with normal cytology
and BMD, HPV18, HPV31, and HPV33 showed some, but less
pronounced, effect on one or both of these parameters. The effect
was either limited to women with normal cytology or to women
with BMD, or, in case of XCIN3 rate, only evident after excluding
the women having HPV16 infections. The relatively small size of
the subgroups of women with type-specific persistence of non-
HPV16 types is a likely reason that effects of these types on XCIN3
rate were only marginal.
Distinguishing hrHPV types with a decreased clearance rate may
have implications for future screening algorithms. When con-
sidering implementation of hrHPV genotyping in cervical screen-
ing, it is important to evaluate the time point at which genotyping
is performed. Genotyping may well be cost-effective when it is
limited to baseline samples, and generic hrHPV testing is
applied during follow-up. We also calculated clearance rates when
clearance was defined as a negative generic hrHPV test instead
of a negative RLB result, and it appeared that clearance rates were
only 5–10% lower when assessed by a generic hrHPV test. Besides,
reduced clearance rates were found for the same hrHPV types as
found by a negative RLB result, that is, HPV16, HPV18, HPV31,
and HPV33. Therefore, we feel that information about type-specific
clearance in cervical screening can be provided with sufficient
accuracy by generic hrHPV testing during follow-up.
For screening algorithms, it is also important to determine the
optimal testing moment during follow-up. As about one-third of
women with cleared infections revealed clearance between 6 and 18
months, a conservative management with a longer waiting period
may be considered, particularly for women with normal cytology,
as this is likely to result in less medical procedures. However, the
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sfollow-up time point should not only be targeted on the hrHPV
clearance time but also on the risk of XCIN3 for the different HPV
types (Berkhof et al, 2006). Notably, women with either BMD or an
HPV16-positive normal smear have a clearly increased risk of
XCIN3, and should be recalled early or perhaps even referred for
colposcopy at baseline. Owing to the small size of the subgroups,
our data are inconclusive concerning the surveillance of women
with normal cytology and an HPV18, HPV31, or HPV33 infection.
For hrHPV-positive women with normal cytology and without
HPV16, HPV18, HPV31, and HPV33, a conservative management
with repeat testing at a later time point seems feasible. Currently,
our data are incorporated in cost-effectiveness studies to assess the
optimal algorithm for the follow-up of hrHPV-positive women
with normal cytology or BMD.
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